Yingru Xu

474 total citations
20 papers, 322 citations indexed

About

Yingru Xu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Yingru Xu has authored 20 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in Yingru Xu's work include Pelvic floor disorders treatments (3 papers), MicroRNA in disease regulation (3 papers) and RNA modifications and cancer (3 papers). Yingru Xu is often cited by papers focused on Pelvic floor disorders treatments (3 papers), MicroRNA in disease regulation (3 papers) and RNA modifications and cancer (3 papers). Yingru Xu collaborates with scholars based in China, United States and Australia. Yingru Xu's co-authors include Xinyi Liao, Ruyuan Yu, Libing Song, Shuxia Zhang, Miaoling Tang, Jun Li, Xingui Wu, Yameng Hu, Meisongzhu Yang and Ziwen Li and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Yingru Xu

18 papers receiving 318 citations

Peers

Yingru Xu
Hui Qian China
Wenrong Xu China
Zhiwei Peng China
Hailin Pang China
Zeng-Hong Li Hong Kong
Yamin Qiao China
Maria Criscuolo Italy
Zhengqin Gu China
Hui Qian China
Yingru Xu
Citations per year, relative to Yingru Xu Yingru Xu (= 1×) peers Hui Qian

Countries citing papers authored by Yingru Xu

Since Specialization
Citations

This map shows the geographic impact of Yingru Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingru Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingru Xu more than expected).

Fields of papers citing papers by Yingru Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingru Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingru Xu. The network helps show where Yingru Xu may publish in the future.

Co-authorship network of co-authors of Yingru Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Yingru Xu. A scholar is included among the top collaborators of Yingru Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yingru Xu. Yingru Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Yingru, et al.. (2025). Preparation and saltiness characterization of NaCl-loaded O/W emulsion gel. Journal of Food Engineering. 399. 112619–112619. 1 indexed citations
2.
3.
4.
Tang, Miaoling, Shuxia Zhang, Meisongzhu Yang, et al.. (2024). Infiltrative Vessel Co-optive Growth Pattern Induced by IQGAP3 Overexpression Promotes Microvascular Invasion in Hepatocellular Carcinoma. Clinical Cancer Research. 30(10). 2206–2224. 7 indexed citations
5.
Zhang, Shuxia, Xincheng Li, Xingui Wu, et al.. (2024). Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT -methylated glioblastoma. Science Translational Medicine. 16(767). eado1573–eado1573. 5 indexed citations
6.
Liao, Xinyi, Haiqing Zheng, Shuxia Zhang, et al.. (2023). Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis. Molecular Cancer Research. 21(7). 648–663. 6 indexed citations
7.
Xu, Yingru, Xincheng Li, Shuxia Zhang, et al.. (2023). CircMMP2(6,7) Cooperates with β-Catenin and PRMT5 to Disrupt Bone Homeostasis and Promote Breast Cancer Bone Metastasis. Cancer Research. 84(2). 328–343. 12 indexed citations
8.
Chen, Suwen, Yameng Hu, Xinyi Liao, et al.. (2022). NKX2-8/PTHrP Axis-Mediated Osteoclastogenesis and Bone Metastasis in Breast Cancer. Frontiers in Oncology. 12. 907000–907000. 7 indexed citations
9.
Zhang, Shuxia, Xinyi Liao, Suwen Chen, et al.. (2022). Large Oncosome‐Loaded VAPA Promotes Bone‐Tropic Metastasis of Hepatocellular Carcinoma Via Formation of Osteoclastic Pre‐Metastatic Niche. Advanced Science. 9(31). e2201974–e2201974. 29 indexed citations
10.
11.
Tang, Miaoling, Meisongzhu Yang, Geyan Wu, et al.. (2021). Epigenetic Induction of Mitochondrial Fission Is Required for Maintenance of Liver Cancer–Initiating Cells. Cancer Research. 81(14). 3835–3848. 52 indexed citations
12.
13.
Xu, Yingru, Shuxia Zhang, Xinyi Liao, et al.. (2021). Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling. Molecular Cancer. 20(1). 98–98. 78 indexed citations
14.
Zhang, Shuxia, Yingru Xu, Chan Xie, et al.. (2020). RNF219/α‐Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications. Advanced Science. 8(4). 2001961–2001961. 30 indexed citations
15.
16.
Luo, Rubin, et al.. (2015). Case Report Local skin flap with vacuum-seal drainage to facilitate healing of ACS. Genetics and Molecular Research. 14(2). 2953–2957.
17.
Xu, Yingru, et al.. (2013). The effect of synovectomy on bleeding and clinical outcomes for total knee replacement. The Bone & Joint Journal. 95-B(9). 1197–1200. 8 indexed citations
18.
Xu, Yingru, Shuo Huang, & Xiaobing Fu. (2012). Autologous transplantation of bone marrow-derived mesenchymal stem cells: a promising therapeutic strategy for prevention of skin-graft contraction. Clinical and Experimental Dermatology. 37(5). 497–500. 36 indexed citations
19.
Schellens, J. H. M., Geoffrey I. Shapiro, Anne C. Pavlick, et al.. (2011). Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3068–3068. 14 indexed citations
20.
Leijen, Suzanne, Jan H.M. Schellens, Geoffrey I. Shapiro, et al.. (2010). A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3067–3067. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hui Qian Breakdown of academic impact, for papers by Wenrong Xu Breakdown of academic impact, for papers by Zhiwei Peng Breakdown of academic impact, for papers by Hailin Pang Breakdown of academic impact, for papers by Zeng-Hong Li Breakdown of academic impact, for papers by Yamin Qiao Breakdown of academic impact, for papers by Maria Criscuolo Breakdown of academic impact, for papers by Zhengqin Gu
Rankless by CCL
2026